Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Cardiovascular benefits of sodium-glucose cotransporter 2 inhibitors in diabetic and nondiabetic patients

Fig. 3

Primary cardiorenal outcomes in diabetic and nondiabetic patients in three large-scale clinical trials. The primary outcome of the DAPA-HF trial is a composite of hospitalization or urgent visit with intravenous therapy for heart failure or death from cardiovascular causes. The primary outcome of the EMPEROR-Reduced trial is a composite of hospitalization for heart failure or death from cardiovascular causes. The primary outcome of the DAPA-CKD trial is a composite of end-stage kidney disease, sustained decline of 50% in eGFR, or renal or cardiovascular death. Cardiorenal protection is seen consistently in patients with or without diabetes. CI, confidence interval

Back to article page